Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH001 in Treatment-Resistant Depression
NCT05800860Phase 2Completed
- Sponsor
- GH Research PLC
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of mebufotenin in treatment-resistant depression (TRD) (3 arms), sponsored by GH Research PLC. Primary endpoint: Mean change in Montgomery-Åsberg Depression Rating Scale from Baseline at Day 7. Started May 2023; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05800860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800860.